Keros Q2 2024 Earnings Report
Key Takeaways
Keros Therapeutics reported a net loss of $45.3 million for the second quarter of 2024, compared to a net loss of $37.5 million for the same period in 2023. The increase in net loss was primarily due to increased research and development expenses.
Keros continued to build upon the progress of all programs across its pipeline in the second quarter of 2024.
Positive regulatory and data updates were received from the elritercept (KER-050) program.
Strong enrollment activity has been observed in the Phase 2 clinical trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension.
Enrollment of the Phase 2 clinical trial of cibotercept (KER-012) is expected to be completed in the fourth quarter of this year.
Keros
Keros
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at June 30, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.